“We are honored to be able to make available tocilizumab in the Philippines, to serve as a new possibility for treatment of severe Covid-19 patients who have not already had access to life-saving drugs. With this development, we hope to make tocilizumab available as widely as possible to help save lives,” said Suchet Rastogi from SRS.

Tocilizumab is approved as a Drug Product for Emergency Use Only (DEU). Tocilizumab will be available in over 200 hospitals in the Philippines. SRS Life Sciences holds the registration for tocilizumab in the Philippines, while AryoGen will produce the therapy, and Biocare Lifesciences will distribute the therapy to hospitals in the Philippines.